voluntarily open avenues for litigation by the consumer.
Nonetheless, just as business is now subject to increasingly severe and stringent governmental regulations and threats covering every aspect of its existence, medical practice will find itself burdened with legislative restrictions stratified to a point of obliterating some of the areas of freedom.
Suspicion bordering on paranoia is focussed on the delivery of health-care services at local, state, and national levels. Any seemingly unethical practice is immediately exposed by the press, and made subject to legislative harangue, with demands to protect the people, leading finally to restriction by laws and regulations.
The recent hearing on Lincomycin and Cleocin, with the subsequent revelation of the toxicities, are examples of what can happen to patients who are at the whims of practitioners writing indiscriminately for "multiple" and "new" drugs without being fully aware of their toxic manifestations.
The public-at-Iarge and those who are concerned about the proper delivery of health-care and the functioning of health care services cannot candidly stand by and allow these practices to go unchallenged. It is, therefore, necessary at this time for responsible practitioners in all facets of the Health Care Delivery System to rise up and do something to save the health care team from destruction. HUGH N. LUNAN, Pharm.D.
Assistant Clinical Professor
and Clinical Coordinator College of Pharmacy and Pharmacol Sciences Howard University, Washington, D.C. 20059 The Need for Pharmacokinetic Data in Diseased Individuals IT HAS ONLY BEEN IN FECENT YEARS THAT PHARMA-COKINETIC DATA has become readily available for many of the drugs being used today. At the present time, however, there are some drugs for which pharmacokinetic data has not been released, or is unknown. Even though the pharmacokinetic data that is available today is a step in the right direction, this is only a beginning for there is an immediate necessity for data dealing with the effects of disease states on drug pharmacokinetics. It is wellknown that various disease states, such as congestive heart failure, diabetes mellitus, cystic fibrosis, etc., significantly alter many of the patient's vital processes, but the relationships between drug pharmacokinetics and the disease state have not been adequately defined. While many investigators are looking at pharmacokinetic parameters in animals and normal human subjects, pharmacokinetic investigations in diseased individuals are not receiving the attention they need. The complete blame for a lack of clinical pharmacokinetic data is not to be put on the investigators in this area. Some of the pharmaceutical companies have thwarted responsible investigation in the area of drug-disease effects on pharmacokinetic parameters. These companies have claimed, for the most part, that they have established other priorities which make them unable to commit funds for support of the grants submitted to them dealing with drugdisease effects on pharmacokinetic parameters. Other companies have not as yet acted on grants submitted to them dealing with this subject.
It is my hope that this appeal will help stimulate pharmacokinetic research in the basic problem areas of drug-disease interactions. It is the responsibility of the pharmaceutical industry to provide pharmacokinetic data on drug products, not only in healthy individuals, but in diseased individuals as well. Once this data is obtained, health practitioners will be able to better understand the influence of diseases on drug pharmacokinetic parameters, and thus will be able to provide better and safer drug management of diseases.
Assistant Professor of Clinical Pharmacy School of Pharmacy West Virginia University Morgantown, West Virginia 26506
Wandering From
Bed to Bed
EIGHT YEARS AGO, I REMEMBER MY "WEEDS AND SEEDS"
professor announcing to us that the Dean had selected four senior students to make hospital rounds with physicians. She chuckled and predicted, "They sure are going to make fools of themselves." I don't know if those ill-prepared and professionally romantic students looked foolish or not. Yet in spite of what happened during those early experiments, ensuing years have found increasing numbers of students, hospital pharmacists, clinical faculty and, too rarely, pharmacy basic science professors and deans "wandering" around hospital wards. Throughout the nation, from community hospitals with private physicians to large teaching hospitals with medical students, interns, residents and attending physicians, pharmacists are attempting to become a member of the health care team on rounds.
As a student at the University of Southern California, as staff pharmacist at Long Beach Memorial Hospital and as a faculty member at both the University of Georgia and Iowa, I have been wandering from bed to bed with physicians for nearly six and one-half years. It has become dogma that rounding is an essential component of clinical pharmacy in the hospital environment. The question to be answered is who if anyone benefits from this time consuming ritual. The patient? The phar-EDITORIALS macist? The medical team? I recall on my first rounds I felt like I had been placed in the cockpit of a Boeing 747 and told to fly. The first clinical question that a physician ever asked me was about the toxic effects of kanamycin. We were standing at the bedside of a patient with pneumonia and a fellow pharmacy student, now practicing acupuncture, answered neuromuscular blockade! The resident smiled and then related his experience with patients who developed nephrotoxicity. And for three years I had been taught that the pharmacist was the most knowledgeable member of the health care team about drugs and that his or her role was a therapeutic consultant to the physician.
When one asks how much do undergraduate pharmacy students contribute on rounds, the answer, from my experience, is often "zilch." Neither physicians nor patients usually benefit from pharmacy students' presence. Their attendance is justified on the basis of the learning experience. However, what does the average student really get out of rounding? Sitting in the cockpit of a Boeing 747 for a round trip flight to London certainly will give anyone an appreciation for the complex task of the pilot but does this appreciation enable the observer to assist in flying the plane? Given enough round trip flights to London, one can learn to be of some help. How many flights does it take? I suspect that in most pharmacy schools the amount of time required to be able to contribute on rounds is far greater than the amount of time students have in this experience. Does flying in the cockpit as an observer improve the performance of the flight attendant?
The ability of a pharmacist to contribute directly to improving the patient's drug therapy on rounds is dependent upon:
1. The individual's knowledge of the literature; 2. The amount of experience in solving drug related problems in patients;
3. The past experience of actually observing therapeutic and toxic response in patients rather than by conversation or chart reading; 4. Knowledge of the patients being seen;
5. The assertiveness of the pharmacist; and 6. The ego security of the physicians involved.
The receptive intern or resident who has prescribed inappropriately often prefers that the pharmacist offer "corrections" in private rather than before physicians and student members of the rounding team. Pragmatically, in a teaching hospital those judgments which consistently direct the pharmacists' contribution toward improved patient care are often best handled outside the rounding situation. Private consultation rather than rounds often provides the greatest direct patient benefit.
Knowledge of the patient's medication profile and problem list are required for the pharmacist to make a contribution on rounds. Nevertheless, far too many of my academic colleagues claiming clinical pharmacist practitioner status make rounds and then promptly depart from the patient care area to attend to academic duties. These individuals do not have time to adequately monitor the patients seen on rounds and therefore have little knowledge of them and are able to make few unsolicited recommendations. Yet patients seen on rounds stimulate the house staff to ask "academic questions" which lead to discussions from which the medical team learn but have no direct effect upon the patients being seen. Under the circumstances it is clear that everyone, except the patient, benefits; but this can be justifiable, if the particular medical service is contributing to the pharmacist's salary as a teacher rather than a consultant.
Frequently physicians are unaware of drug related problems of a patient. If the pharmacist lacks knowledge or assertiveness then it is not brought to the physician's attention and both patient and medical staff derive no benefit from the pharmacist's presence. The traditional justification is that the pharmacist in this situation may learn a great deal from rounding and the expense, salary or tuition, is indirectly assumed by the hospital. Nevertheless, those of us who learn a pearl today will indeed benefit a specific patient sometime in the future. For at least one clinical pharmacist the traditional dogma is rapidly losing its vitality. Rounding is better than no direct patient care contact but we must begin serious exploration of alternatives. 
